The impact of negative publicity on reporting of adverse events for products implicated in an FDA safety alert is well documented. However, the impact of such publicity on drugs closely related to the implicated drug has not been established. We describe the impact of an FDA safety alert of intranasal Zicam cold products formulated with zinc on reporting of adverse events (principally anosmia) for related (non-alert) Zicam products.
